Klinik für Strahlenheilkunde, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1842-53. doi: 10.1007/s00259-010-1484-3. Epub 2010 May 27.
The objective of this study was to evaluate positron emission tomography (PET) using (18)F-fluoro-2-deoxy-D-glucose (FDG) in comparison to volumetry and standardized magnetic resonance imaging (MRI) parameters for the assessment of histological response in paediatric bone sarcoma patients.
FDG PET and local MRI were performed in 27 paediatric sarcoma patients [Ewing sarcoma family of tumours (EWS), n = 16; osteosarcoma (OS), n = 11] prior to and after neoadjuvant chemotherapy before local tumour resection. Several parameters for assessment of response of the primary tumour to therapy by FDG PET and MRI were evaluated and compared with histopathological regression of the resected tumour as defined by Salzer-Kuntschik.
FDG PET significantly discriminated responders from non-responders using the standardized uptake value (SUV) reduction and the absolute post-therapeutic SUV (SUV2) in the entire patient population (SUV, p = 0.005; SUV2, p = 0.011) as well as in the subgroup of OS patients (SUV, p = 0.009; SUV2, p = 0.028), but not in the EWS subgroup. The volume reduction measured by MRI/CT did not significantly discriminate responders from non-responders either in the entire population (p = 0.170) or in both subgroups (EWS, p = 0.950; OS, p = 1.000). The other MRI parameters alone or in combination were unreliable and did not improve the results. Comparing diagnostic parameters of FDG PET and local MRI, metabolic imaging showed high superiority in the subgroup of OS patients, while similar results were observed in the population of EWS.
FDG PET appears to be a useful tool for non-invasive response assessment in the group of OS patients and is superior to MRI. In EWS patients, however, neither FDG PET nor volumetry or standardized MRI criteria enabled a reliable response assessment to be made after neoadjuvant treatment.
本研究旨在评估正电子发射断层扫描(PET)联合(18)F-氟代-2-脱氧-D-葡萄糖(FDG)与体积测量和标准化磁共振成像(MRI)参数在评估儿科骨肉瘤患者组织学反应中的作用。
27 例儿科肉瘤患者[尤文氏肉瘤家族肿瘤(EWS),n=16;骨肉瘤(OS),n=11]在新辅助化疗前和局部肿瘤切除前进行 FDG PET 和局部 MRI 检查。评估和比较了几种参数,以评估 FDG PET 和 MRI 对原发性肿瘤治疗反应的评估,并与 Salzer-Kuntschik 定义的切除肿瘤的组织学回归进行比较。
FDG PET 通过标准化摄取值(SUV)降低和治疗后绝对 SUV(SUV2)在整个患者人群(SUV,p=0.005;SUV2,p=0.011)以及 OS 患者亚组(SUV,p=0.009;SUV2,p=0.028)中,显著区分了应答者和无应答者,但在 EWS 亚组中没有。MRI/CT 测量的体积减少在整个人群中(p=0.170)或在两个亚组中(EWS,p=0.950;OS,p=1.000)均不能显著区分应答者和无应答者。单独或联合使用其他 MRI 参数是不可靠的,也不能改善结果。比较 FDG PET 和局部 MRI 的诊断参数,代谢成像在 OS 患者亚组中显示出较高的优越性,而在 EWS 患者中则观察到相似的结果。
FDG PET 似乎是一种有用的工具,可用于 OS 患者的非侵入性反应评估,并且优于 MRI。然而,在 EWS 患者中,新辅助治疗后,FDG PET 或体积测量或标准化 MRI 标准均不能可靠地评估反应。